harmaline has been researched along with Parkinson Disease in 7 studies
Harmaline: A beta-carboline alkaloid isolated from seeds of PEGANUM.
harmaline : A harmala alkaloid in which the harman skeleton is methoxy-substituted at C-7 and has been reduced across the 3,4 bond.
Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of the present study was to examine the influence of a unilateral 6-hydroxydopamine (6-OHDA)-induced partial lesion of both the substantia nigra pars compacta (SNc, A9) and retrorubral field (RRF, A8) on the tremor evoked by harmaline." | 7.78 | 6-OHDA injections into A8-A9 dopaminergic neurons modelling early stages of Parkinson's disease increase the harmaline-induced tremor in rats. ( Berghauzen, K; Kolasiewicz, W; Kuter, K; Nowak, P; Ossowska, K; Schulze, G, 2012) |
| "The aim of the present study was to examine the influence of a unilateral 6-hydroxydopamine (6-OHDA)-induced partial lesion of both the substantia nigra pars compacta (SNc, A9) and retrorubral field (RRF, A8) on the tremor evoked by harmaline." | 3.78 | 6-OHDA injections into A8-A9 dopaminergic neurons modelling early stages of Parkinson's disease increase the harmaline-induced tremor in rats. ( Berghauzen, K; Kolasiewicz, W; Kuter, K; Nowak, P; Ossowska, K; Schulze, G, 2012) |
| " Two lines of evidence strongly suggest that the bursting pallidal activities are a consequence of the interruption of the nigrostriatal dopaminergic pathway: (1) the percentage of bursting pallidal neurons is proportional to the amount of degeneration in the pars compacta of the ipsilateral substantia nigra; (2) chronic administration of dopamine antagonists, haloperidol and reserpine, reproduces in intact monkeys the bursting activities observed in lesioned animals." | 1.26 | Effects of interruption of the nigrostriatal pathway and of dopaminergic agents on the spontaneous activity of globus pallidus neurons in the awake monkey. ( Filion, M, 1979) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (42.86) | 18.7374 |
| 1990's | 1 (14.29) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Banerjee, R | 1 |
| Kumar, M | 1 |
| Gaurav, I | 1 |
| Thakur, S | 1 |
| Thakur, A | 1 |
| Singh, K | 1 |
| Karak, S | 1 |
| Das, R | 1 |
| Chhabra, M | 1 |
| Wang, YH | 1 |
| Samoylenko, V | 1 |
| Tekwani, BL | 1 |
| Khan, IA | 1 |
| Miller, LS | 1 |
| Chaurasiya, ND | 1 |
| Rahman, MM | 1 |
| Tripathi, LM | 1 |
| Khan, SI | 1 |
| Joshi, VC | 1 |
| Wigger, FT | 1 |
| Muhammad, I | 1 |
| Kolasiewicz, W | 1 |
| Kuter, K | 1 |
| Berghauzen, K | 1 |
| Nowak, P | 1 |
| Schulze, G | 1 |
| Ossowska, K | 1 |
| Cobuzzi, RJ | 1 |
| Neafsey, EJ | 1 |
| Collins, MA | 1 |
| Filion, M | 1 |
| Hassler, R | 1 |
| Wagner, A | 1 |
| Lamarre, Y | 1 |
| Joffroy, AJ | 1 |
| Dumont, M | 1 |
| De Montigny, C | 1 |
| Grou, F | 1 |
| Lund, JP | 1 |
1 review available for harmaline and Parkinson Disease
| Article | Year |
|---|---|
Locomotor activity and speed of movements in relation to monoamine-acting drugs.
Topics: Animals; Atropine; Basal Ganglia; Cats; Corpus Striatum; Dopamine; gamma-Aminobutyric Acid; Harmalin | 1975 |
6 other studies available for harmaline and Parkinson Disease
| Article | Year |
|---|---|
In-silico Prediction of the Beta-carboline Alkaloids Harmine and Harmaline as Potent Drug Candidates for the Treatment of Parkinson's disease.
Topics: Alkaloids; Carbolines; Harmaline; Harmine; Humans; Molecular Docking Simulation; Neurodegenerative D | 2021 |
Composition, standardization and chemical profiling of Banisteriopsis caapi, a plant for the treatment of neurodegenerative disorders relevant to Parkinson's disease.
Topics: Alkaloids; Animals; Banisteriopsis; Beverages; Biflavonoids; Catechin; Ethnopharmacology; Harmaline; | 2010 |
6-OHDA injections into A8-A9 dopaminergic neurons modelling early stages of Parkinson's disease increase the harmaline-induced tremor in rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Agents; Animals; Central Nervous System Stimulants; Cereb | 2012 |
Differential cytotoxicities of N-methyl-beta-carbolinium analogues of MPP+ in PC12 cells: insights into potential neurotoxicants in Parkinson's disease.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Cations; Cell Death; Culture Media; Energy Metabolism; Harmali | 1994 |
Effects of interruption of the nigrostriatal pathway and of dopaminergic agents on the spontaneous activity of globus pallidus neurons in the awake monkey.
Topics: Animals; Apomorphine; Corpus Striatum; Evoked Potentials; Globus Pallidus; Haloperidol; Haplorhini; | 1979 |
Central mechanisms of tremor in some feline and primate models.
Topics: Animals; Brain; Cats; Cerebellum; Disease Models, Animal; Electromyography; Haplorhini; Harmaline; M | 1975 |